- Home
- BANC vs CELC Comparison
BANC vs CELC Comparison
Compare BANC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANC | CELC |
|---|---|---|
| Founded | 1941 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BANC | CELC |
|---|---|---|
| Price | $20.46 | $104.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $20.06 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.7M | 836.7K |
| Earning Date | 01-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $1,019,965,000.00 | N/A |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $10.89 | N/A |
| P/E Ratio | $19.55 | ★ N/A |
| Revenue Growth | ★ 147.22 | N/A |
| 52 Week Low | $11.52 | $7.58 |
| 52 Week High | $20.30 | $112.64 |
Technical Indicators
Market Signals| Indicator | BANC | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 71.45 | 60.93 |
| Support Level | $19.11 | $98.50 |
| Resistance Level | $19.77 | $112.00 |
| Average True Range (ATR) | 0.41 | 3.98 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 87.58 | 57.03 |
Price Performance
Historical ComparisonAbout BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.